Australia markets closed

Biocartis Group NV (BCART.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
3.0100+0.1600 (+5.61%)
At close: 05:35PM CET

Biocartis Group NV

Generaal De Wittelaan 11 B
Mechelen 2800
Belgium
32 1 563 20 00
https://www.biocartis.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees484

Key executives

NameTitlePayExercisedYear born
Mr. Herman VerrelstCEO & Exec. Director468.75kN/A1974
Mr. Jean-Marc RoelandtChief Financial OfficerN/AN/A1965
Mr. Piet HouwenChief Operating OfficerN/AN/A1968
Mr. Benoit DevogelaereChief Technology OfficerN/AN/A1981
Mr. Geert MaertensChairman of Scientific Advisory Board & Chief Scientific OfficerN/AN/AN/A
Renate DegraveHead of IR & Corp. CommunicationsN/AN/AN/A
Ms. Susy SpruytHead of People & OrganizationN/AN/A1968
Dr. Erwin SablonHead of R&D and Alliance ManagementN/AN/A1965
Mr. Reginald Van GenechtenHead of Manufacturing & Supply ChainN/AN/A1966
Mr. Dirk ZimmermannGlobal Head of Pharma Collaborations & PartneringN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers formalin fixed, paraffin embedded solid biopsy tests, including diagnostic products, such as Idylla BRAF, KRAS, NRAS-BRAF, NRAS, and EGFR mutation tests; and research products, which include Idylla MSI and NRAS-BRAF-EGFR S492R mutation assays. It also provides plasma liquid biopsy tests comprising diagnostic products that include Idylla ctKRAS and ctNRAS-BRAF mutation tests; and research products consisting of Idylla ctBRAF and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with AstraZeneca to develop and commercialize Idylla based molecular tests in support of AstraZeneca's pharmaceutical products; Bristol-Myers Squibb Company for the registration of Idylla MSI Test as companion diagnostic test for metastatic colorectal cancer in China; and Endpoint Health, Inc. for the development and commercialization of a novel companion diagnostic test based on Idylla molecular diagnostics platform. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. Biocartis Group NV was founded in 2007 and is headquartered in Mechelen, Belgium.

Corporate governance

Biocartis Group NV’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.